Jessie J Wang, Yanrui Song, Hongyan Sun, Annie X An, Likun Zhang, Davy X Ouyang, and Henry QX Li
Immunotherapy development for prostate cancer has been fairly limited (excluding the approval of Sipuleucel-T). It is generally accepted that prostate cancer needs to be tackled by combination regimens of immunotherapies alongside chemotherapy and targeted agents.
For preclinical testing, this means that models are required which are suitable to evaluate immunotherapies (e.g. immunocompetent models), combined with the genetic features of human disease which targeted agents are aimed at.
GEMM models recapitulate some molecular aspects of human prostate cancer but are difficult to use for efficacy studies due to spontaneous tumours. Compound mutant mice (e.g. Pten null and Kras G12D; Pten null) are well characterised but are costly to breed. We have developed prostate cancer tumour homograft models which combine immunocompentence, genetic complexity, and operational simplicity.